Global Interventional Oncology Market Size, Trend & Opportunity Analysis Report, by Technique (Ablation Therapies (Radiofrequency Ablation (RFA), Microwave Ablation (MWA), Cryoablation, Laser Ablation, Irreversible Electroporation (IRE)), Embolisation The

Market Definition and Introduction

The global interventional oncology market was valued at USD 2.68 billion in 2024 and is anticipated to reach USD 6.92 billion by 2035, expanding at a CAGR of 9.0% during the forecast period (2024–2035). Interventional oncology has emerged as perhaps one of the most significant sub-specialities of minimally invasive medicine in which the technological sophistication of procedures meets extant life-prolonging therapies. As the burden of cancer keeps increasing in the world, the current market confines its definition with an increased amalgam of imaging innovations, miniaturisation of devices, and procedural precision, enabling clinicians to diagnose, monitor, and treat tumours with accuracy while reducing collateral damage. The advancement in the adoption of interventional oncology throughout developed and emerging healthcare ecosystems keeps pushing forward because, with time, systemic therapies are becoming more and more personalised and focused, so that their need for localised and, ideally, minimally invasive methods continues to stimulate interventional oncology adoption.

Interventional oncology procedures typically involve shorter hospital stays, fewer post-operative complications, and superior quality of life after treatment compared with conventional surgical procedures, the therapeutic landscape is changing towards patient-centric outcomes. The most popular are microwave ablation and radiofrequency . Both these techniques have entered the mainstream due to their ability to destroy practically all tumours that are operable and their use in embolisation therapies that deprive blood supply from the affected tumour masses. All this further broadens the clinical applications of hepatocellular carcinoma, lung, kidney, and bone cancers. Growth further intensifies as more and more clinical evidence and guideline endorsements validate these therapies as standard-of-care in specific cancer pathways.

Increasing penetration of ablation systems, embolic agents, and sophisticated biopsy instruments is continuously expanding portfolios by device manufacturers to feed a wide variety of clinical settings. Strategic collaborations among the medtech corporation, hospitals, and research institutes hasten product approvals while robust funding for oncology research goes into commercial adoption. Meanwhile, the convergence of some of these AI-driven imaging solutions with interventional oncology enriches procedural confidence with picture-guided navigation systems remapping the precision of treatment delivery. These demand and supply potent forces are propelling an era of disruptive growth in the interventional oncology market.

Recent Developments in the Industry

In February 2024, Boston Scientific announced, the commercial rollout of the company's new advanced cryoablative platform in Europe aimed at treating inoperable lung tumours. Insightfully combining real-time imaging with an enhanced probe design, this system seeks to improve treatment outcomes and accuracy in patient care.

In July 2024, the company launched this new generation of embolic microspheres within the tumour embolisation segment, specifically developed to provide superior vascular targeting, decrease procedure duration, and greatly improve outcomes for patients with liver cancer.

In March 2025, Philips Healthcare introduced to the public its AI-based imaging and navigation platform dedicated to supporting interventional oncology procedures. This improvement enables real-time visualisation of tumours and precise placement of catheters, thus ensuring safer and more effective procedures.

In September 2023, With the approval, which was granted, Siemens Healthineers made its inroads with the ablation device for microwave treatment of hepatic tumours. This also served to provide better portfolio coverage in medical oncology devices among the offerings and extend market penetration in the U.S.

In June 2024, AngioDynamics disclosed a plan to invest USD 100 million into a dedicated oncology research hub to catalyse the development of both ablation and embolisation technologies, which further illustrates industry commitment to innovation.

Market Dynamics

Courses in minimal invasive procedure adoption will change treatment pathways in oncology.

To adjust minimally invasive approaches while not increasing their workload and allowing maximal accuracy, the increasing occurrence of cancers, with specific emphasis on liver, lung and kidney tumours, is taxing the clinicians. Instead of open surgical methods, radiofrequency/microwave ablation techniques are taking precedence because they offer reduced hospital stay and fast recovery after surgery. Alongside varying shifts of global health policy towards value-based health care and patient-centred outcomes, this transformation brings out a trend towards minimally invasive approaches toward treatment and management.

Advances in imaging technologies are boosting the growth of the market across modalities.

MRI, CT and ultrasound systems have been integrated into the treatment workflows. It had become possible with AI-driven visualisation devices, which allow clinicians to map even the most difficult-to-imagine tumours through a controlled, unprecedented visualisation, enabling accuracy in diagnosis and therapy. Consistent with developments, clinician trust accrues alongside an increase in interventional procedure eligibility.

Regulatory pressure and high R&D investments are driving competitive innovation.

More regulatory agencies in North America and Europe approve devices that satisfy stringent standards of safety and efficacy. Such a rigidity is a disadvantage to the players as well as a motivator to invest heavily in research and clinical trials, thus producing next-generation embolic agents, ablation devices, and biopsy tools. The phenomenon is creating a competitive innovation hub, where differentiation occurs via technology breakthroughs and integrated solutions.

Barriers of costs, training, and facilities are restraining global penetration.

Interventional oncology bears most of the promises for progressive growth but suffers from several challenges in terms of costs and accessibility, particularly for low-income economies. Costs of imaging equipment, device systems, and procedural training serve as a critical restraint. In most regions, there are also few interventional radiologists and oncologists, thus inhibiting the wide adoption and emphasising the need for training and capacity-building initiatives.

Emerging opportunities in AI, personalised medicine, and hybrid procedures

Precision medicine is taking centre stage. Interventional oncology will play a key role in complementing systemic therapies, particularly because of its ability to directly reach the tumour while minimising toxicity. Hybrid procedures that combine ablation or embolisation with immunotherapy or chemotherapy are becoming more prevalent in practice. There are even AI-assisted platforms integrating diagnosis, planning, and steps to redefine the industry in interventional oncology as a promising growth avenue for stakeholders in the industry.

Attractive Opportunities in the Market

AI-Driven Imaging Growth – Expanding AI-enabled visualisation platforms for precision-guided oncology procedures across clinical settings.
Hybrid Treatment Models – Combining systemic therapies with localised interventional procedures to maximise cancer treatment efficacy.
Biopsy Innovation Surge – Development of advanced biopsy tools enhancing diagnostic accuracy and procedural safety worldwide.
Emerging Market Expansion – Rapid adoption in Asia-Pacific and Latin America driven by healthcare infrastructure upgrades.
Personalised Oncology Care – Tailored interventional solutions aligned with patient-specific cancer biology and treatment pathways.
Eco-Certified Devices – Growing regulatory preference for sustainable and compliant interventional device manufacturing practices.
Digital Workflow Integration – Seamless adoption of integrated digital platforms streamlining procedural planning and execution.
Training and Education Growth – Rising investments in specialist training programmes addressing workforce shortages in oncology.
Device Miniaturisation Trends – Continuous advancements in smaller, flexible devices enabling access to complex anatomical sites.
Strategic M&A Activity – Consolidation across medtech leaders is accelerating technology transfer and expanding product portfolios.

Report Segmentation

By Technique:
Ablation Therapies (Radiofrequency Ablation (RFA), Microwave Ablation (MWA), Cryoablation, Laser Ablation, Irreversible Electroporation (IRE))
Embolisation Therapies (Transarterial Chemoembolization (TACE), Transarterial Radioembolization (TARE))
Biopsy Techniques (Core Needle Biopsy, Fine Needle Aspiration (FNA))
Targeted Therapy Delivery Systems (Drug-Eluting Beads, Targeted Therapy Delivery Systems)
Image-Guided Procedures (Ultrasound Guidance, CT Scan Guidance, MRI Guidance, Fluoroscopy Guidance)

By Procedure: Tumour Ablation, Tumour Biopsy, Vascular Interventions, Palliative Care

By Application: Liver Cancer, Lung Cancer, Kidney Cancer, Prostate Cancer, Breast Cancer, Other Cancer

By End-use: Hospitals, Specialty Clinics, Others

By Region: North America (U.S., Canada, Mexico), Europe (UK, Germany, France, Spain, Italy, Spain, Rest of Europe), Asia-Pacific (China, India, Japan, Australia, South Korea, Rest of Asia-Pacific), LAMEA (Brazil, Argentina, UAE, Saudi Arabia (KSA), Africa Rest of Latin America)

Key Market Players

Boston Scientific Corporation, Medtronic plc, Terumo Corporation, Merit Medical Systems, Siemens Healthineers, Johnson & Johnson (Ethicon), BTG International Ltd., AngioDynamics Inc., Varian Medical Systems (now part of Siemens), and Philips Healthcare.

Report Aspects

Base Year: 2024
Historic Years: 2022, 2023, 2024
Forecast Period: 2024-2035
Report Pages: 293

Dominating Segments

Ablation therapies are a dominant form of treatment in a minimally invasive form of treatment, which is effective across tumour locations for cancer.

Patients unfit for surgical resection can benefit from ablation therapies that account for a major market share, where they possibly offer efficacy cures. Radiofrequency and microwave ablation techniques have been proven to destroy malignant tissues quite accurately, predictably while sparing surrounding healthy structures. Outpatient ease, fewer complications, and higher clinical acceptability are driving widespread adoption. Of note, this modality continues to acquire a market niche in guidelines advocacy for its use in liver, kidney, and lung cancers.

Embolisation therapies gain momentum through targeted tumour treatment in hepatic oncology.

On an addendum, embolisation therapies, including transarterial chemoembolization (TACE), are, together with radioembolization, widely used in the management of liver cancers, which present a serious burden in the incidence of oncology worldwide. The two ways act in a sense that they obstruct the blood supply to a tumour while, at the same time, deliver therapeutic agents, thus twofold opportunity in cytotoxicity and shrinkage of the tumour. The developing clinical trials and augmented developments in the embolic agents have fostered the growth, especially in the side of Asia-Pacific region, where the threat of hepatocellular carcinomas remains.

Tumour ablation procedure remains a common front-end interventional oncology solution.

Tumour ablation is now one of the fastest-growing interventional procedures. It is increasingly being used to treat small localised tumours. Compared with an open surgical approach, its shorter recovery time propels it as a preferred treatment modality. Also, ablation is being combined with systemic therapies increasingly, so that patient outcomes may improve. Advances in technology are improving heat control and precision in difficult-to-reach sites.

Tumour biopsy consolidates its foundation as a cornerstone for personalised oncology diagnostics.

Tumour biopsy remains the most paramount procedure in interventional oncology, giving a diagnosis confirmed and defining individualised management principles. With the heightening introduction of targeted therapies, accurate and timely biopsies have become prerequisites for any successful patient-specific care. Technological advances have given a pathway for insights into more advanced biopsy needles and imaging integration that greatly improve safety as well as yield and diagnostic accuracy. Its supremacy will continue as oncological gravitate towards precision medicine.

Key Takeaways

Ablation Therapies Lead – Minimally invasive ablation systems dominate cancer treatment with reduced risk and improved survival.
Embolisation Expansion – Targeted embolisation solutions gain traction in managing complex liver tumours across global markets.
Biopsy Role Strengthens – Diagnostic precision through advanced tumour biopsy tools remains indispensable in personalised medicine.
AI-Enabled Imaging – Artificial intelligence integrated with imaging platforms elevates procedural accuracy and clinician confidence.
North America Dominates – Strong oncology infrastructure and regulatory innovation sustain market leadership in this region.
Asia-Pacific Growth Surge – Expanding cancer prevalence and healthcare investment accelerate the adoption of interventional oncology.
Regulatory Stringency – Compliance with global device approval standards drives safer and more effective product innovations.
Hybrid Therapies Rising – A Combination of interventional techniques with systemic treatments enhances cancer care effectiveness.
High R&D Spending – Continuous investments by leading players accelerate advancements in ablation and embolisation technologies.
M&A Consolidation Trend – Industry consolidation fosters broader portfolios and strengthens global interventional oncology presence.

Regional Insights

North American interventional oncology market thrives on advanced healthcare infrastructure and innovation.

North America continues to be the ostensible largest regional market owing to its strong healthcare infrastructure, cancer incidence, and advanced uptake of minimally invasive procedures. The U.S. leads in clinical utilisation and device innovation for reimbursement policies and promising investments in oncology R&D. The fast-track approvals for innovative devices at regulatory authorities like the FDA further strengthen the regional status as the hub of interventional oncology.

Europe consolidates leadership in precision oncology with good regulatory and clinical frameworks.

Europe is a very strong market based on regulation, high health expenses, and networks for advanced oncology research. So much investment has taken place in intervention oncology, especially in the use of embolisation therapies for liver cancer management in countries such as Germany, the UK, and France. The innovative push has come from regulatory alignment under CE marking and joint clinical trials; emphasis on evidence-based adoption continues to sustain growth across the region.

Asia-Pacific is leading the quickest growth of markets, with an increasing cancer burden and the modernisation of healthcare

Asia-Pacific will be the fastest regional market, growing with rapid urbanisation and increasing cases of cancer. It is also improving healthcare systems. Nations such as China, India, and Japan have skyrocketed by government funding for building an oncology facility, especially in adopting technologies like embolisation and thermal ablation. The enormous supply of patients and awareness about advanced invasive procedures drive demand, currently supported by increased clinical trial activity across the region.

LAMEA leverages emerging healthcare initiatives and investments to scale intervention oncology adoption

Latin America, the Middle East, and Africa are slowly but steadily emerging markets, unlike developed countries. Brazil and the UAE are the front-runners in adopting the modernisation of healthcare systems move which drives the demand for interventional procedures. Yet, the contrary fact is that access to skilled professionals and sophisticated equipment is lacking. Increased partnerships with global med-tech players and increased governmental support across regional areas are anticipated to improve market penetration in the coming decade.

Core Strategic Questions Answered in This Report

Q. What is the expected growth trajectory of the interventional oncology market from 2024 to 2035?

The global interventional oncology market is projected to grow from USD 2.68 billion in 2024 to USD 6.92 billion by 2035, registering a CAGR of 9.0%. This growth is primarily driven by increasing adoption of ablation and embolisation therapies, technological integration in imaging, and expanding cancer burden worldwide.

Q. Which key factors are fuelling the growth of the interventional oncology market?

Several key factors are propelling market growth:

Rising cancer prevalence necessitating minimally invasive and targeted treatment modalities
Increasing R&D investments in ablation and embolisation device innovations
Expanding adoption of AI-enabled imaging platforms for enhanced treatment precision
Strong clinical evidence and regulatory approvals endorsing interventional therapies
Growing healthcare infrastructure investments across emerging markets such as the Asia-Pacific

Q. What are the primary challenges hindering the growth of the interventional oncology market?

Major challenges include:

High costs of imaging systems and interventional devices are restraining global affordability
Limited access to trained professionals in developing healthcare systems
Stringent regulatory hurdles are slowing down device approval timelines
Unequal reimbursement frameworks across geographies are impacting adoption rates
Infrastructure gaps in emerging economies are limiting procedural availability

Q. Which regions currently lead the interventional oncology market in terms of market share?

North America currently leads the interventional oncology market due to advanced oncology infrastructure, high patient awareness, and favourable reimbursement policies. Europe closely follows with regulatory-driven precision oncology adoption, while Asia-Pacific is expected to dominate in growth rate due to rapid healthcare modernisation and rising cancer incidence.

Q. What emerging opportunities are anticipated in the interventional oncology market?

The market is ripe with new opportunities, including:

Expansion of hybrid interventional and systemic treatment models
Integration of AI-enabled imaging platforms into oncology workflows
Development of advanced ablation and embolisation systems for complex tumours
Growing demand in emerging markets due to healthcare expansion initiatives
Strategic collaborations driving research and commercial adoption of next-generation devices

Key Benefits for Stakeholders

The report offers a quantitative assessment of market segments, emerging trends, projections, and market dynamics for the period 2024 to 2035.
The report presents comprehensive market research, including insights into key growth drivers, challenges, and potential opportunities.
Porter's Five Forces analysis evaluates the influence of buyers and suppliers, helping stakeholders make strategic, profit-driven decisions and strengthen their supplier-buyer relationships.
A detailed examination of market segmentation helps identify existing and emerging opportunities.
Key countries within each region are analysed based on their revenue contributions to the overall market.
The positioning of market players enables effective benchmarking and provides clarity on their current standing within the industry.
The report covers regional and global market trends, major players, key segments, application areas, and strategies for market expansion. Show more